Cargando…

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

PURPOSE: Although aromatase inhibitor (AI) treatment is effective in estrogen receptor–positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy number alterations (SCNAs), is important in breast cancer development and pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuster, Eugene F., Gellert, Pascal, Segal, Corrinne V., López-Knowles, Elena, Buus, Richard, Cheang, Maggie Chon U., Morden, James, Robertson, John, Bliss, Judith M., Smith, Ian, Dowsett, Mitch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446335/ https://www.ncbi.nlm.nih.gov/pubmed/32914010 http://dx.doi.org/10.1200/PO.18.00286

Ejemplares similares

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
por: López-Knowles, Elena, et al.
Publicado: (2014)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
por: Smith, Ian, et al.
Publicado: (2020)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
por: Bliss, Judith M., et al.
Publicado: (2023)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
por: Feng, Juan, et al.
Publicado: (2023)

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study
por: Bliss, Judith, et al.
Publicado: (2015)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Sex Differences in Brain Aromatase Activity: Genomic and Non-Genomic Controls
por: Balthazart, Jacques, et al.
Publicado: (2011)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer
por: Zhang, Meiying, et al.
Publicado: (2017)

The genomic environment around the Aromatase gene: evolutionary insights
por: Castro, L Filipe C, et al.
Publicado: (2005)

Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells
por: Drainas, Alexandros P., et al.
Publicado: (2020)

Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification
por: Tovey, Holly, et al.
Publicado: (2019)

Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes
por: Cerboni, Silvia, et al.
Publicado: (2017)

Intrinsic S phase checkpoint enforced by an antiproliferative oncosuppressor cytokine
por: Mallucci, Livio, et al.
Publicado: (2021)

Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability
por: Mathias, Carolina, et al.
Publicado: (2020)

Aromatase inhibition in advanced prostatic cancer: preliminary communication.
por: Shearer, R. J., et al.
Publicado: (1990)

Amniotes co-opt intrinsic genetic instability to protect germ-line genome integrity
por: Sun, Yu H., et al.
Publicado: (2023)

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
por: Sadasivam, Kirithika, et al.
Publicado: (2023)

TP53 loss initiates chromosomal instability in fallopian tube epithelial cells
por: Bronder, Daniel, et al.
Publicado: (2021)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
por: Ellis, Matthew J., et al.
Publicado: (2012)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992)

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
por: Macaulay, V. M., et al.
Publicado: (1994)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rao65hq4o2vgbng2jk5a827g4h